Interceptor Plus

Verify with FDA CVM →

179 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
179
Total Reports
8
Deaths Reported
450.0%
Death Rate

Active Ingredients

Interceptor Plus

Administration Routes

OralUnknownSubcutaneous

Species Affected

Dog 179

Most Affected Breeds

Retriever - Labrador 26
Crossbred Canine/dog 22
Retriever - Golden 14
Shepherd Dog - Australian 8
Boxer (German Boxer) 8
Shepherd Dog - German 8
Dog (unknown) 6
Terrier - Yorkshire 6
Shih Tzu 5
Siberian Husky 5

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 76
Vomiting 26
Seizure NOS 21
Diarrhoea 17
Emesis (multiple) 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Decreased appetite 5
Mental impairment NOS 5
Ataxia 5
Panting 5
Tremor 5
Walking difficulty 5

Outcome Breakdown

Ongoing
103 (57.5%)
Outcome Unknown
38 (21.2%)
Recovered/Normal
30 (16.8%)
Died
5 (2.8%)
Euthanized
3 (1.7%)

Data Summary

Metric Value
Total adverse event reports 179
Reports involving death 8
Case-fatality rate (reported events) 450.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Interceptor Plus Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 179 adverse event reports referencing Interceptor Plus, including 8 reports in which the animal died — a 450.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Interceptor Plus. Reported administration routes include Oral, Unknown, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Interceptor Plus reports are Dog (179 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (26), Crossbred Canine/dog (22), Retriever - Golden (14) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Interceptor Plus are Lack of efficacy (endoparasite) - heartworm (76), Vomiting (26), Seizure NOS (21), Diarrhoea (17). Of the 179 reports with a coded outcome, Ongoing is the leading category at 57.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Interceptor Plus.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial